Capture Vascular, Inc.
FDA-cleared clot removal technology, broad indications, addresses a large unmet clinical need in coronary & peripheral applications in a U.S. market of $800M+.
Capture was founded in May 2013 to pursue commercialization of its platform FDA-cleared technology that addresses the unmet clinical need for quick & effective clot removal in a wide range of diseases. The versatile design & broad indications allow for treatment of both coronary & peripheral vessels, while providing numerous advantages over currently available devices. Our exit strategy entails the sale of the technology to a tier one strategic.